Literature DB >> 19930098

The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis.

S A Mousavi1, K E Berge, T P Leren.   

Abstract

The LDL receptor (LDLR) plays an essential role in the regulation of plasma (LDL) cholesterol concentrations by virtue of its ability to clear plasma LDL. Down-regulation of the LDLR by proprotein convertase subtilisin/kexin 9 (PCSK9) has recently emerged as a regulatory mechanism that controls plasma LDL cholesterol concentrations. Studies in which PCSK9 is over-expressed in mice, have demonstrated that PCSK9, by enhancing hepatic LDLR degradation, decreases the availability of the LDLR for LDL uptake, resulting in increased plasma LDL cholesterol levels. However, PCSK9 has also recently been shown to mediate down-regulation of surface receptors other than the LDLR, suggesting that it may have much broader roles than initially thought.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19930098     DOI: 10.1111/j.1365-2796.2009.02167.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  31 in total

Review 1.  Genetics of atherothrombosis and thrombophilia.

Authors:  Anders Mälarstig; Anders Hamsten
Journal:  Curr Atheroscler Rep       Date:  2010-05       Impact factor: 5.113

2.  PCSK9 is present in human cerebrospinal fluid and is maintained at remarkably constant concentrations throughout the course of the day.

Authors:  Yan Q Chen; Jason S Troutt; Robert J Konrad
Journal:  Lipids       Date:  2014-05       Impact factor: 1.880

3.  Novel method for reducing plasma cholesterol: a ligand replacement therapy.

Authors:  G M Anantharamaiah; Dennis Goldberg
Journal:  Clin Lipidol       Date:  2015-01-01

Review 4.  Cholesterol, the central lipid of mammalian cells.

Authors:  Frederick R Maxfield; Gerrit van Meer
Journal:  Curr Opin Cell Biol       Date:  2010-06-02       Impact factor: 8.382

5.  High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol.

Authors:  Greg Welder; Issam Zineh; Michael A Pacanowski; Jason S Troutt; Guoqing Cao; Robert J Konrad
Journal:  J Lipid Res       Date:  2010-06-05       Impact factor: 5.922

6.  Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin/kexin type 9.

Authors:  Yuan-Lin Guo; Jun Liu; Rui-Xia Xu; Cheng-Gang Zhu; Na-Qiong Wu; Li-Xin Jiang; Jian-Jun Li
Journal:  Clin Drug Investig       Date:  2013-12       Impact factor: 2.859

7.  Peripheral vascular atherosclerosis in a novel PCSK9 gain-of-function mutant Ossabaw miniature pig model.

Authors:  Ahmad F Hedayat; Kyoung-Ha Park; Taek-Geun Kwon; John R Woollard; Kai Jiang; Daniel F Carlson; Amir Lerman; Lilach O Lerman
Journal:  Transl Res       Date:  2017-11-03       Impact factor: 7.012

Review 8.  PCSK9: From Basic Science Discoveries to Clinical Trials.

Authors:  Michael D Shapiro; Hagai Tavori; Sergio Fazio
Journal:  Circ Res       Date:  2018-05-11       Impact factor: 17.367

Review 9.  Genetically modified pigs to model human diseases.

Authors:  Tatiana Flisikowska; Alexander Kind; Angelika Schnieke
Journal:  J Appl Genet       Date:  2014-02       Impact factor: 3.240

10.  Accumulation of Pericardial Fat Is Associated With Alterations in Heart Rate Variability Patterns in Hypercholesterolemic Pigs.

Authors:  Domingo E Uceda; Xiang-Yang Zhu; John R Woollard; Christopher M Ferguson; Ioannis Patras; Daniel F Carlson; Samuel J Asirvatham; Amir Lerman; Lilach O Lerman
Journal:  Circ Arrhythm Electrophysiol       Date:  2020-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.